

Table 1: Primary and secondary endpoints from the ROAR study

	ITT ATC cohort (n=36)		BRAF V600E assessable (n=33)	
	Investigator assessed	Independent assessment	Investigator assessed	Independent assessment
ORR (95% CI)	56% (38.1% to 72.1%)	53% (35.5% to 69.6%)	61% (42.1% to 77.1%)	58% (39.2% to 74.5%)
CR (patients)	8% (3)	6% (2)	9% (3)	6% (2)
PR (patients)	47% (17)	47% (17)	52% (17)	52% (17)
Median DOR (95% CI)	14.4 months (7.4 to 43.6 months)	13.6 months (3.8 to not reached)	NR	NR
Median PFS (95% CI)	6.7 months (4.7 to 13.8 months)	5.5 months (3.7 to 12.9 months)	NR	NR
Overall survival	14.5 months (95% CI 6.8 to 23.2 months)	NR	NR	NR

ATC: anaplastic thyroid cancer; CI: confidence interval; CR: complete response; PR: partial response; DOR: duration of response; ITT: intention to treat; NR: not reported; ORR: overall response rate; PFS: progression-free survival